Bendamustine and hypercalcaemia Patient Reports February 13, 2012

Bendamustine Side Effects Report #5701519-3
Bendamustine side effect was reported by a Physician from UNITED STATES on Mar 26, 2008. Female patient, 47 years of age, weighting 187.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Bendamustine. After drug was administered, patient experienced the following side effects: hypercalcaemia, thrombocytopenia. Bendamustine dosage: 50 MG/M2 INTRAVENOUS. During the same period patient was treated with VELCADE, RITUXIMAB. Patient was hospitalized. Patient recovered.

Bendamustine Side Effects Report #5977649-8
Bendamustine side effect was reported by a Physician from UNITED STATES on Nov 20, 2008. Female patient, 47 years of age, weighting 187.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Bendamustine. After drug was administered, patient experienced the following side effects: disease progression, hypercalcaemia, non-hodgkin's lymphoma, thrombocytopenia. Bendamustine dosage: 50 MG/M2 INTRAVENOUS. During the same period patient was treated with VELCADE, RITUXIMAB. Patient was hospitalized. Patient recovered.

Bendamustine Side Effects Report #5981489-3
Bendamustine side effect was reported by a Physician from UNITED STATES on Nov 26, 2008. Female patient, 47 years of age, weighting 187.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Bendamustine. After drug was administered, patient experienced the following side effects: hypercalcaemia, thrombocytopenia. Bendamustine dosage: 50 MG/M2 INTRAVENOUS. During the same period patient was treated with VELCADE, RITUXIMAB. Patient was hospitalized. Patient recovered.

Bendamustine Side Effects Report #5993028-1
Bendamustine side effect was reported by a Physician from UNITED STATES on Dec 03, 2008. Female patient, 47 years of age, weighting 187.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Bendamustine. After drug was administered, patient experienced the following side effects: atelectasis, blood albumin decreased, blood alkaline phosphatase increased, blood magnesium decreased, dehydration, diarrhoea, dyspnoea, hypercalcaemia, nausea . Bendamustine dosage: 50 MG/M2 INTRAVENOUS. During the same period patient was treated with VELCADE, RITUXIMAB, RHINOCORT, ALLEGRA, ALBUTEROL, FLOVENT, MAXZIDE, COUMADIN. Patient was hospitalized. Patient recovered.